Damon Runyon News

October 2, 2019
New Discovery


Peter J. Turnbaugh, PhD (Damon Runyon Innovator '16-'20), at the University of California, San Francisco, discusses his recent discovery that eating a diet of cooked food fundementally changes the microbes living in the gut compared to a diet of raw foods.


September 18, 2019
New Discovery


Surprising new research from Jason M. Sheltzer, PhD (Damon Runyon-Rachleff Innovator ’18 - ’20) and colleagues at Cold Spring Harbor Laboratory suggests why 97% of cancer drugs in clinical trials fail to stop cancer in patients and never make it to market.


September 11, 2019
Latest News


Yung S. Lie, PhD, President and CEO of Damon Runyon Cancer Research Foundation, sat down with Denver Frederick, host of “The Business of Giving” on AM 970 The Answer WNYM in New York City, to discuss the history and strategy of the organization.  


September 10, 2019
Awards and Honors


Two Damon Runyon alumni have been awarded the 2019 Lasker Awards, which “honor innovations that have advanced knowledge, treatment, or prevention of disease,” and are considered to be one of the highest international honors in medical research. H. Michael Shepard, PhD (Damon Runyon Fellow ’78-’80), shares the prize for his contribution to the discovery of the breast cancer treatment Herceptin. Jacques F.A.P. Miller, PhD (Damon Runyon Grantee ’73-’75), shares the award for pioneering immunology research that has led to many new therapeutic approaches. 


September 9, 2019
Latest News


For the ninth year in a row, Damon Runyon has earned a 4-star rating from Charity Navigator for “demonstrating strong financial health and commitment to accountability and transparency.” 


August 7, 2019
Latest News


The warnings to use sunscreen are very real -- skin is the largest organ of the body and the most vulnerable to DNA damage caused by the sun’s ultraviolet rays. Basal cell carcinoma (BCC), a form of skin cancer, is the most common cancer in the United States with 3 million cases diagnosed annually. These cancers tend to grow slowly, usually developing on sun-exposed areas such as the head and neck, and treatment involves surgically removing the tumor. Usually this doesn’t present complications, but some individuals develop frequent recurrences of BCC that require multiple painful surgeries and scars.  


July 24, 2019
New Discovery


CAR (chimeric antigen receptor) T cell immunotherapy has generated much excitement in the last two years— saving the lives of some blood cancer patients when other treatments have failed. Developing CAR T therapies for solid tumors has been far more challenging. That could be changing. Marcela V. Maus, MD, PhD (Damon Runyon-Rachleff Innovator ’17-’20), and colleagues at Massachusetts General Hospital have turned CAR T cells into virtual armored vehicles, capable of launching deadly strikes against glioblastoma brain tumors.


July 23, 2019
Latest News


Fifteen brilliant scientists from across the country were named Damon Runyon Fellows. The recipients of this prestigious, four-year award are outstanding postdoctoral scientists conducting basic and translational cancer research in the laboratories of leading senior investigators. The Fellowship encourages the nation's most promising young scientists to pursue careers in cancer research by providing them with independent funding ($231,000 total) to work on creative, high-risk projects.


July 16, 2019
New Discovery


Nicholas Arpaia, PhD (Damon Runyon Fellow ’13–’16), and Tal Danino, PhD, at Columbia University, have genetically programmed E. Coli bacteria to uncloak tumor cells and activate the immune system to attack them. The innovative approach eliminated tumors and distant metastases in mice and may lead to therapies that combat cancer more effectively in patients, without side effects.


July 16, 2019
Latest News


The Damon Runyon Cancer Research Foundation has named four outstanding young scientists as recipients of the prestigious Damon Runyon-Sohn Pediatric Cancer Fellowship Award, committing nearly $1 million to help address a critical shortage of funding for pediatric cancer research.